Recon: FDA Re-examines Arcadia Parkinson's Drug, EU Calls for Renewed Push Against Preventable Diseases

• FDA re-examines safety of controversial new drug (CNN) (Reuters) (CNBC) (Endpoints)
• Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short (CNBC) (Reuters)
• AbbVie downplays Rova-T setback as Q1 beats (BioPharma Dive) (Fierce) (Reuters) (Forbes)
• Mereo pulls IPO, blaming ‘challenging’ stock market conditions (Fierce)(Endpoints)
• Senti scientific co-founder Wilson Wong designs the SUPRA — a new, high performance model CAR-T (Endpoints) (Fierce)
• Leftover Drugs Are Fueling the Opioid Epidemic. Now Google Maps Is Helping Families Get Rid of Them (Fortune) (Washington Post) (Engadget)

• EU wants coordinated vaccine push against measles, other diseases (Reuters) (EC)
• Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources (Reuters)
• Ocrevus fuels fast start to year for Roche (BioPharma Dive) (Fierce)) (Reuters) (Bloomberg)
• Shire Q1 sales rise 7% driven by immunology and new treatments (FInancial Times) (BioPharma Dive) (Reuters)
• Pioneering prostate treatment for tens of thousands of men gets NHS green light (The Telegraph) (NICE) (BBC News) (PharmaTimes)
• 'Gene map for depression' sparks hopes of new generation of treatments (The Guardian) (Reuters)
• Johnson & Johnson appeal of $151M hip implant ruling succeeds after judge finds talk of Iraqi bribes tainted case (Fierce) (Reuters)
• Shire takeover may take months to finish (The Boston Globe)

• How High Drug Prices and Big Lobbying Budgets Go Together for Big Pharma (Fortune-KHN)
• Feds almost ready to charge drugmakers—and executives—in generics price-fixing probe (Fierce)
• AbbVie Must Escape the Shadow of Humira's Decline (Bloomberg)
• Amazon failed to disrupt the prescription drug business with Drugstore.com. Could a second try succeed? (STAT)
• You’ve heard about precision medicine. Now get ready for precision drug ads (STAT-$)
• CRISPR legend Jennifer Doudna helps some recent college grads launch a diagnostics upstart (Endpoints)
• The Drug Supply Chain Security Act: A progress report (BioPharma Dive)

• Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra (Endpoints)
• GSK tips its hat on new deals, reviews incentives as Hal Barron cooks up a turnaround plan for its lackluster R&D group (Endpoints)
• Celgene’s disclosures about ozanimod this week spur analysts’ fears of a lengthy delay for a key drug (Endpoints)
• Neurocrine presents positive analysis of Phase III Ingrezza data (The Pharma Letter)
• AllTrials audit finds most top public funders lack research transparency policies (Fierce)
• Alder builds case for CGRP migraine drug eptinezumab (FIerce)
• Saniona cleared for second phase of Prader-Willi syndrome trial (Fierce)
• FDA could convene second advisory panel to re-examine safety of Acadia Pharma drug (STAT-$)
• What's the Total Cost of One CAR T-Cell Treatment? (Medscape)
• Astellas files experimental AML therapy (PharmaTimes)

• Fresenius Medical Care North America Launches Corporate Charitable Foundation (Press)
• Medineering touts first uses of Robotic Endoscopy system (MassDevice)
• Restech acquires Mederi Medical (MassDevice)
• Agfa Receives FDA 510(k) Clearance for DR 800 Multi-purpose Digital Imaging System (Press)
• Mobius Imaging Receives 510(k) Clearance for Airo CT Pediatric Applications (Press)
• Medical Device Startup Blink Device Company Announces 510(k) Clearance of TwitchView Quantitative Monitor for Neuromuscular Blockade and Hires VP of Sales and Marketing (Press)

• Trauma centers serving vulnerable patients on shaky financial ground (Reuters)
• Judge rules in Baltimore's favor in suit over federal cuts to teen pregnancy prevention program (The Baltimore Sun)
• 31 more sick in romaine lettuce E. coli outbreak (USA Today)
• Will Amazon Bend the Cost Curve for Health Care? (Bloomberg)
• The Trump Administration Wants to Take the Mystery Out of How Much Hospitals Charge Patients (Fortune)

• FDA Advisory Committee Calendar

• BD Vacutainer EDTA & BD Vacutainer Lithium Heparin Tubes – risk of incorrect results for lead testing or other assays using ASV methodology (MHRA)
• Couple sentenced for operating fake online pharmacy (MHRA)
• German minister calls for clearer labeling of unhealthy food (Reuters)
• ABPI explores the future of medicines (PMLiVE)
• Pfizer takes aim at UK’s health tech industry (PMLiVE)
• Lords slam government commitment to life sciences strategy (PharmaTimes)
• U.K. Healthcare Startup Said to Have Posted Fake Reviews Online (Bloomberg)
• EU Invests Funds, Working On Standards To Spur AI Growth (Law360-$)

• Taiwan accuses China of risk to global health over WHO ban (The Straits Times)
• Twice rejected by Lilly, Adocia mounts recovery with diabetes drug deal (Fierce)

• Amitabh Bachchan: 'Forget the Avengers, it took real heroes to make India polio-free' (The Guardian)

• TGA stakeholder survey 2017 (TGA)
• Prostate cancer: early detection saves lives (The Australian)

• What We Heard - Proposals for prescription drug transparency (Health Canada)

• Income, education tied to physical function in old age (Reuters)
• A startup promised to make health care ‘refreshingly simple.’ Building the business has been anything but (STAT)
• Commentary: Shame won't help opioid addicts (Chicago Tribune)